- SID Score
- 7.8/10
- Fair value
- $287.87
- Generated
- Sep 17, 2026
- Model
- claude-haiku-4-5-20251001
Johnson & Johnson is trading at $268.58 with a market capitalization of $505.8 billion, presenting a mixed investment picture characterized by solid operational performance offset by valuation concerns. The stock demonstrates moderate upside potential with a fair value estimate of $287.87 (8.4% upside), though this conflicts with the significantly lower analyst average price target of $207.08, suggesting substantial disagreement among market participants. With a P/E ratio of 20.29 and SID Score of 7.8/10, JNJ presents a balanced risk-reward profile suitable for disciplined value-oriented investors seeking healthcare exposure.
Recent earnings performance has been consistently solid, with Q2 2026 EPS of $2.90 exceeding estimates of $2.85, Q1 2026 EPS of $2.70 slightly beating expectations of $2.67, and Q4 2025 EPS of $2.46 marginally missing estimates of $2.47, demonstrating reliable albeit unspectacular earnings generation. The company's factor grades reveal strong growth credentials (Grade A) and solid dividend policy (Grade B), though profitability receives only a C rating and value assessment a concerning D grade, suggesting the stock may be trading above intrinsic value on traditional metrics. With limited financial statement data available, deeper analysis of revenue growth, margin trends, and return on equity metrics is constrained, though the consistent earnings execution provides some confidence in operational stability.
The 50-day moving average of $262.93 sits just below the current price of $268.58, indicating a slight upward technical bias, while the 200-day moving average of $243.44 is substantially lower, confirming a strong uptrend over the longer-term horizon. The RSI(14) reading of 46.2 suggests the stock is neither overbought nor oversold, positioning it in neutral technical territory with room to move in either direction without extreme valuation signals. This technical setup indicates the stock has room to appreciate toward the fair value estimate of $287.87 before encountering meaningful resistance or overbought conditions.
Analyst & Insider Sentiment
The analyst consensus rating of "Buy" with an average price target of $207.08 presents a major red flag, as this implies approximately 23% downside from current levels and directly contradicts both the fair value estimate and the buy recommendation. Insider activity has been mixed, with CEO Joaquin Duato executing a substantial series of stock sales totaling 246,582 shares on August 13, 2026 (followed by a partial repurchase of 123,291 shares on the same date), which could signal executive concerns about valuation levels. The offsetting insider buying activity is modest, with only Elizabeth Forminard's sale of 9,344 shares on August 6 reported, suggesting limited insider confidence in near-term appreciation.
The significant disconnect between the fair value estimate ($287.87) and analyst average price target ($207.08) represents a critical valuation risk, indicating substantial uncertainty about the company's intrinsic worth and potential for significant downside correction if the analyst consensus proves correct. Recent insider selling activity, particularly by senior executives, raises concerns about management's confidence in current valuations and may presage negative developments or profit-taking before potential stock declines. Additional risks include the modest 0.02% dividend yield (surprisingly low for a company with a "B" dividend grade), potential pharmaceutical patent expirations, regulatory challenges in drug pricing, and exposure to healthcare policy changes.
Johnson & Johnson represents a moderately attractive holding for conservative healthcare-focused investors seeking stable earnings exposure, supported by consistent quarterly EPS performance and a Buy analyst consensus, though the valuation disconnect warrants caution regarding entry points and position sizing. The company's strong growth grade and acceptable technical positioning suggest reasonable near-term upside potential to the $287.87 fair value estimate, but the substantial gap with analyst price targets demands careful risk management and possibly a wait-and-see approach until valuation clarity improves. Investors should monitor the next earnings release (scheduled for Q3 2026), watch for changes in insider trading patterns, and reassess the analyst consensus before committing significant capital, as the current mixed signals suggest a "hold" stance rather than an aggressive accumulation opportunity.
